Abstract: In recent years, the interest in nonthermal plasma dynamics has grown significantly, within both industry and research. This has been driven by the development of several novel cold plasma ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Greg Daugherty has worked 25+ years as an editor and writer for major publications and websites. He is also the author of two books. Katie Miller is a consumer financial services expert. She worked ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

The company laid out its restructuring plans in a regulatory document. These include a workforce reduction of around 20%. Before market open, Recursion disclosed in a tersely worded regulatory filing ...

A startling milestone has been reached in Florida's war against the invasive Burmese pythons eating their way across the Everglades. The Conservancy of Southwest Florida reports it has captured and ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

When I run cargo run -p ty -- check a.py, I get: Finished `dev` profile [unoptimized + debuginfo] target(s) in 0.29s Running `target/debug/ty check a.py` WARN ty is pre-release software and not ready ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...